Panobinostat

Panobinostat
Clinical data
Trade names	Farydak
Other names	LBH-589
AHFS/Drugs.com	Monograph
License data	US DailyMed: Panobinostat;
Routes of; administration	By mouth
ATC code	L01XH03 (WHO) ;
Legal status
Legal status	AU: S4 (Prescription only); US: ℞-only; EU: Rx-only; In general: ℞ (Prescription only);
Pharmacokinetic data
Bioavailability	21%
Protein binding	90%
Metabolism	CYP3A (40%), CYP2D6, CYP2C19
Elimination half-life	37 hours
Excretion	Fecal (44–77%), renal (29–51%)
Identifiers
	IUPAC name (2E)-N-hydroxy-3-[4-({[2-(2-methyl-1H-indol-3-yl)ethyl]amino}methyl)phenyl]acrylamide;
CAS Number	404950-80-7 ;
PubChem CID	6918837;
IUPHAR/BPS	7489;
DrugBank	DB06603 ;
ChemSpider	5294028 ;
UNII	9647FM7Y3Z;
KEGG	D10319 ;
ChEBI	CHEBI:85990 ;
CompTox Dashboard (EPA)	DTXSID40193506 ;
ECHA InfoCard	100.230.582
Chemical and physical data
Formula	C21H23N3O2
Molar mass	349.434 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES O=C(NO)\C=C\c1ccc(cc1)CNCCc3c2ccccc2[nH]c3C;
	InChI InChI=1S/C21H23N3O2/c1-15-18(19-4-2-3-5-20(19)23-15)12-13-22-14-17-8-6-16(7-9-17)10-11-21(25)24-26/h2-11,22-23,26H,12-14H2,1H3,(H,24,25)/b11-10+ ; Key:FPOHNWQLNRZRFC-ZHACJKMWSA-N ;
	(what is this?) (verify)

Panobinostat, sold under the brand name Farydak, is a medication used for the treatment of multiple myeloma. It is a hydroxamic acid and acts as a non-selective histone deacetylase inhibitor (pan-HDAC inhibitor).

Panobinostat was approved for medical use in the United States in February 2015, and in the European Union in August 2015. However, in March 2022, it was withdrawn in the United States.